Connor, Clark & Lunn Investment Management (CC&L)’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-167,538
| Closed | -$3.38M | – | 1259 |
|
|
2021
Q3 | $3.38M | Buy |
167,538
+79,527
| +90% | +$1.6M | 0.02% | 417 |
|
|
2021
Q2 | $3.29M | Sell |
88,011
-147,873
| -63% | -$5.52M | 0.02% | 443 |
|
|
2021
Q1 | $6.03M | Sell |
235,884
-64,017
| -21% | -$1.64M | 0.03% | 321 |
|
|
2020
Q4 | $6.61M | Buy |
299,901
+1,930
| +0.6% | +$42.5K | 0.04% | 283 |
|
|
2020
Q3 | $5.36M | Buy |
297,971
+25,585
| +9% | +$460K | 0.04% | 289 |
|
|
2020
Q2 | $6.92M | Sell |
272,386
-22,789
| -8% | -$579K | 0.05% | 251 |
|
|
2020
Q1 | $5.42M | Buy |
295,175
+109,325
| +59% | +$2.01M | 0.05% | 232 |
|
|
2019
Q4 | $4.09M | Buy |
+185,850
| New | +$4.09M | 0.03% | 301 |
|
|
2017
Q4 | – | Sell |
-68,975
| Closed | -$397K | – | 884 |
|
|
2017
Q3 | $397K | Sell |
68,975
-10,300
| -13% | -$59.3K | ﹤0.01% | 664 |
|
|
2017
Q2 | $251K | Buy |
79,275
+17,575
| +28% | +$55.6K | ﹤0.01% | 705 |
|
|
2017
Q1 | $210K | Buy |
61,700
+15,600
| +34% | +$53.1K | ﹤0.01% | 794 |
|
|
2016
Q4 | $133K | Buy |
46,100
+20,200
| +78% | +$58.3K | ﹤0.01% | 821 |
|
|
2016
Q3 | $152K | Buy |
25,900
+5,500
| +27% | +$32.3K | ﹤0.01% | 755 |
|
|
2016
Q2 | $61K | Sell |
20,400
-7,700
| -27% | -$23K | ﹤0.01% | 825 |
|
|
2016
Q1 | $151K | Sell |
28,100
-400
| -1% | -$2.15K | ﹤0.01% | 740 |
|
|
2015
Q4 | $338K | Buy |
28,500
+5,600
| +24% | +$66.4K | ﹤0.01% | 608 |
|
|
2015
Q3 | $188K | Buy |
22,900
+6,500
| +40% | +$53.4K | ﹤0.01% | 647 |
|
|
2015
Q2 | $229K | Hold |
16,400
| – | – | ﹤0.01% | 541 |
|
|
2015
Q1 | $394K | Buy |
+16,400
| New | +$394K | ﹤0.01% | 424 |
|